VOLUME 10 ISSUE 1 2024

ISSN 2454 – 3055

INTERNATIONAL JOURNAL OF ZOOLOGICAL INVESTIGATIONS

Forum for Biological and Environmental Sciences

Published by Saran Publications, India

International Journal of Zoological Investigations Vol. 10, No. 1, 490-509 (2024)

International Journal of Zoological Investigations
Contents available at Journals Home Page: www.ijzi.net
Editor-in-Chief: Prof. Ajai Kumar Srivastav
Published by: Saran Publications, Gorakhpur, India

ISSN: 2454-3055

Ethnopharmacology and Cancer: Bridging Traditional Healing Practice with Modern Pharmacognosy

Tripathi Arpan Kumar[1]*, Sudha M.[2], Kareemulla Shaik[3], Gadewar Manoj M.[4], Deepha V.[5] and Chandra Shekhara Rao G.[6]

[1]Kamla Institute of Pharmacy, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh 490020, India
[2]Department of Pharmacology, Faculty of Pharmacy, Dr.M.G.R. Educational and Research Institute, Maduravoyal, Chennai 600095, Tamil Nadu, India
[3]M. M. College of Pharmacy (Maharishi Markandeshwar Deemed University), Mullana-Ambala 133207, Haryana, India
[4]Department of Pharmacology, School of Medical and Allied Sciences, K R Mangalam University, Gurgaon122102, Haryana, India
[5]Bannari Amman Institute of Technology, Sathyamangalam, Tamil Nadu, India
[6]Vignan Institute of Pharmaceutical Technology, Duvvada, Visakhapatnam, Andhra Pradesh, India

**Corresponding Author*

Received: 30th October, 2023; **Accepted:** 22nd December, 2023; **Published online:** 28th March, 2024

https://doi.org/10.33745/ijzi.2024.v10i01.054

Abstract: Ethnopharmacology is an interdisciplinary field that explores the traditional knowledge and practices of indigenous communities regarding the therapeutic properties of medicinal plants, bridging it with modern pharmacognosy, which focuses on the scientific study of natural products for drug discovery and development. Cancer, a complex and devastating disease, has long been a target for research and treatment advancement. In recent years, there has been a growing interest in integrating traditional healing practices with modern pharmacognosy approaches to discover potential anticancer agents.

Indigenous communities across the globe have a rich history of using medicinal plants for cancer treatment and management. These traditional remedies, passed down through generations, often possess a holistic approach towards health and well-being, taking into account the individual's physical, mental, and spiritual aspects. By tapping into this vast repository of traditional knowledge, researchers have been able to identify numerous natural compounds with potential anticancer activity.

The field of pharmacognosy complements ethnopharmacology by providing scientific validation and understanding of the active compounds present in medicinal plants. Through various extraction and purification techniques, these compounds can be isolated, characterized, and further studied for their pharmacological properties. This integration of traditional knowledge and modern pharmacognosy techniques has the potential to accelerate the discovery of new anticancer agents, potentially providing alternative or complementary treatment options to conventional therapies. In conclusion, ethnopharmacology and modern pharmacognosy hold great promise in the search for novel anticancer agents. By combining traditional healing practices with scientific validation and understanding, this interdisciplinary approach can unlock the potential of natural products and contribute to the development of more effective and personalized cancer treatments.

Keywords: Ethanopharmacology, Cancer, Medicinal plants, Pharmacognosy, Natural products, Drug discovery

Citation: Tripathi Arpan Kumar, Sudha M., Kareemulla Shaik, Gadewar Manoj M., Deepha V. and Chandra Shekhara Rao G.: Ethnopharmacology and cancer: bridging traditional healing practice with modern pharmacognosy. Intern. J. Zool. Invest. 10(1): 490-509, 2024.

https://doi.org/10.33745/ijzi.2024.v10i01.054

Introduction

Ethnopharmacology is a multidisciplinary field that focuses on the study of traditional medicinal practices and the use of natural substances, primarily plants, for their potential therapeutic properties (Etkin and Elisabetsky, 2005). This field combines elements of ethnobotany, anthropology, pharmacology, and pharmacognosy to explore the traditional knowledge and practices of various cultures related to medicinal plants and their potential applications in modern medicine (Giovannini and Heinrich, 2009).

Ethnopharmacology is a fascinating inter-disciplinary field that delves into the study of traditional medicinal practices and the utilization of natural substances, predominantly derived from plants, for their potential therapeutic applications (Thomas *et al.*, 2009). This multifaceted domain combines elements of ethnobotany, anthropology, pharmacology, and pharmacognosy to investigate the traditional wisdom and practices of diverse cultures pertaining to medicinal plants and their possible integration into modern medicine (Vandebroek *et al.*, 2004). This involves studying and validating the traditional knowledge surrounding the use of plants and herbs for cancer treatment while also conducting in-depth chemical and pharmaco-logical analyses to identify potential anticancer compounds (Pieroni *et al.*, 2004). By bridging the knowledge passed down through generations with rigorous modern scientific methods, researchers aim to unlock new insights into cancer treatment and potentially discover compounds that can augment existing therapies or form the basis for new ones, making this a promising frontier in the quest to conquer cancer (Pardo *et al.*, 2005; de Albuquerque and de Oliveira, 2007).

Importance of integrating traditional healing practices with modern pharmacognosy:

The importance of integrating traditional healing practices with modern pharmacognosy in the context of of cancer. Here are some key reasons why this integration is important:

(i) *Rich Source of Potential Compounds*: Traditional healing practices have evolved over centuries and have identified various plants and natural substances with potential therapeutic properties (Ellen, 1996). These sources can serve as a valuable reservoir of bioactive compounds that could be harnessed for cancer treatment. These compounds may possess unique properties or mechanisms of action that have not been explored in modern medicine.

(ii) *Cultural Relevance*: Traditional healing practices are deeply rooted in the cultures and traditions of various communities. Integrating these practices respects and values cultural knowledge (Waldstein and Adams, 2006). This approach can also make cancer treatments more accessible and acceptable to patients from these communities (Etkin, 1988).

(iii) *Economic and Sustainable Development*: Many traditional remedies are derived from local flora, which can support sustainable practices. Incorporating these practices into modern medicine can provide economic benefits to communities and promote the conservation of medicinal plants and biodiversity (Ten Kate and Laird, 1999).

(iv) *Combating Drug Resistance*: Cancer cells can develop resistance to modern chemotherapy drugs. Traditional remedies may offer alternative pathways to target cancer cells, potentially overcoming drug resistance issues. This diversity in approaches is essential in the battle against cancer (Pieroni and Price, 2006).

(v) *Enhancing Efficacy*: Traditional remedies often involve the use of multiple plants or combinations of compounds. This synergistic effect can enhance the efficacy of treatment and may reduce side effects associated with higher doses of a single drug (Etkin, 2001).

In the fight against cancer, where drug resistance and limited therapeutic options often pose formidable challenges, traditional remedies may offer fresh perspectives. The synergy of compounds in these remedies could enhance treatment efficacy and reduce the side effects associated with higher doses of single drugs (Elisabetsky, 1991). Additionally, the integration of traditional practices can expedite drug development, saving precious time by building on the knowledge that has already been accrued (Laird, 2002). A holistic approach to cancer treatment is another advantage, providing patients with complementary and integrative therapies that not only address the physical aspects of their illness but also consider the cultural and psychological dimensions. Furthermore, the exploration of traditional practices may uncover novel therapeutic targets and pathways, expanding the scope of cancer research (Balick, 1990; Heinrich and Gibbons, 2001).

Ethnopharmacology: *A Window into Traditional Healing*:

Ethnopharmacology is a multidisciplinary field that explores the traditional knowledge and practices of various cultures regarding the use of medicinal plants and natural substances for therapeutic purposes (Berkes *et al.*, 2000). It involves the systematic study of how different societies, often indigenous or traditional, have employed natural remedies to treat and prevent diseases, including cancer. It also addresses sustainability and conservation concerns by promoting responsible practices in harvesting and cultivating medicinal plants, ensuring their long-term availability while safeguarding biodiversity (Posey, 2002). In the context of cancer research, ethnopharmacology serves as a beacon of hope, holding the promise of identifying novel leads for cancer treatment, overcoming drug resistance, and advancing global healthcare by making cancer treatments more accessible and culturally relevant. This integration acknowledges the importance of respecting and learning from diverse cultures while working together to confront one of the most formidable diseases of our time: cancer (Reyes-García *et al.*, 2008).

Role of indigenous knowledge and traditional healing practices:

Indigenous knowledge and traditional healing practices play a pivotal role in the context of paramount significance for several reasons:

(i) *Ancient Wisdom*: Indigenous communities and traditional healers have accumulated centuries of knowledge about the use of medicinal plants and natural substances (McDade *et al.*, 2007). This knowledge represents a vast reservoir of wisdom passed down through generations, often containing valuable insights into the treatment of various ailments, including cancer (Moerman, 2007).

(ii) *Rich Biodiversity*: Many indigenous cultures inhabit regions with rich biodiversity, which means they have identified and utilized a diverse range of plant species with potential medicinal properties. This biodiversity offers a unique source of bioactive compounds that may hold promise for cancer treatment (Browner *et al.*, 1988).

(iii) *Local Relevance*: Traditional healing practices are deeply rooted in the culture and daily life of indigenous communities. They are often specifically tailored to local conditions, making them particularly relevant and effective in addressing health issues in those areas (Bristow *et*

al., 2003).

(iv) *Holistic Approach*: Indigenous healing practices often take a holistic approach to healthcare. They consider not only the physical symptoms of an illness but also the psychological, spiritual, and cultural dimensions of health. This holistic approach aligns with the principles of patient-centred care (Adams *et al.*, 2011a).

(v) *Community-Based Healthcare*: Traditional healers often provide care within their own communities. This community-based healthcare is more accessible and culturally sensitive, which can be especially important in areas with limited access to modern medical facilities (Adams *et al.*, 2011b).

(vi) *Sustainability*: Traditional healing practices often involve the sustainable use of local flora. This supports the conservation of medicinal plants and biodiversity, promoting long-term availability (Aggarwal *et al.*, 2011).

(vii) *Cultural Preservation*: The integration of traditional healing practices into modern medicine helps preserve cultural heritage. It acknowledges the importance of respecting and maintaining these cultural traditions, particularly in the face of globalization (Anonymous, 1879).

In the sphere of cancer research, the role of indigenous knowledge and traditional healing practices is to facilitate a harmonious collaboration between the ancient wisdom of these practices and the precision of modern science. Through rigorous scientific investigation, the safety and efficacy of traditional remedies and their bioactive compounds are validated, potentially unlocking novel approaches to cancer treatment (Bingel *et al.*, 2011). This integration is a powerful testament to the value of combining centuries of cultural wisdom with contemporary scientific rigor, all in the relentless pursuit of solutions for one of the most daunting challenges of our era: cancer. It underscores the importance of acknowledging and learning from diverse cultures while advancing the fight against this formidable disease (Bisht *et al.*, 2007).

Case studies showcasing ethnopharmacological discoveries:

The types of ethnopharmacological discoveries in the context of cancer research have been reported in the literature (Booker *et al.*, 2012). These discoveries showcase the potential of bridging traditional healing practices with modern pharmacognosy. Please note that for the most recent case studies and developments, it's advisable to refer to scientific journals and databases for up-to-date information (Buenz *et al.*, 2004).

(i) *Artemisinin and Traditional Chinese Medicine*: Artemisinin, derived from the sweet wormwood plant (Artemisia annua), is a prime example of ethnopharmacological discovery. This compound, which has been used in traditional Chinese medicine for centuries, was found to have potent anti-malarial properties (Bye *et al.*, 1995). More recently, research has shown its potential in cancer treatment due to its ability to selectively target and kill cancer cells (Carhart-Harris *et al.*, 2012).

(ii) *Vinca Alkaloids from Periwinkle*: Vinca alkaloids, derived from the Madagascar periwinkle (Catharanthus roseus), are well-known in cancer treatment. These compounds, used traditionally for various ailments, have been instrumental in the development of chemotherapy drugs for leukemia and other cancers (Carrera-Bastos *et al.*, 2011).

(iii) *Paclitaxel from the Pacific Yew Tree*: Paclitaxel, sourced from the bark of the Pacific yew tree (*Taxus brevifolia*), is another example of a traditional remedy turned cancer treatment. Indigenous communities had used the yew tree for medicinal purposes, and paclitaxel was discovered to be highly effective in treating various cancers (Casselman and Heinrich, 2011).

(iv) *South American Medicinal Plants*: Traditional knowledge of medicinal plants in South America has led to the discovery of bioactive compounds with anti-cancer properties. For example, the compound lapachol from the lapacho tree is

known for its anti-tumor effects (Sweeney *et al.*, 2023).

(v) *Madagascar Periwinkle in Childhood Leukemia*: Traditional healers in Madagascar have long used *Catharanthus roseus* for various treatments. Researchers discovered that its alkaloids, vincristine and vinblastine, were remarkably effective in treating childhood leukemia, revolutionizing cancer therapy (Potter *et al.*, 2020).

(vi) *Chinese Skullcap and Scutellaria barbata*: These traditional Chinese herbs have shown promise in cancer treatment. Research has identified bioactive compounds within these herbs that exhibit anti-tumor and anti-inflammatory properties (AACR Project GENIE Consortium, 2017).

Traditional Chinese herbs like *Chinese skullcap* and *Scutellaria barbata* have also been subjects of ethnopharmacological research. These herbs, deeply embedded in Chinese traditional medicine, have revealed bioactive compounds with anti-tumor and anti-inflammatory properties, offering new avenues for cancer treatment (Smyth *et al.*, 2020). These case studies serve as compelling testaments to the potential of integrating indigenous knowledge and traditional healing practices with modern pharmacognosy. They illuminate the path towards more effective, culturally sensitive, and innovative cancer treatments, providing hope for patients and communities worldwide. For the most current case studies, scientific literature and databases remain essential resources (Micheel *et al.*, 2018).

Cancer: A Global Health Challenge:

The economic ramifications of cancer are substantial, encompassing not only the direct costs associated with diagnosis and treatment but also indirect costs such as lost productivity due to illness and caregiving responsibilities (Green *et al.*, 2015). The utilization of healthcare resources, from diagnostic equipment and medication to the expertise of healthcare personnel and the infrastructure of hospitals, places a considerable burden on healthcare systems. Furthermore, health disparities persist, affecting various populations differently and leading to unequal outcomes in cancer care. Beyond the physical and economic aspects, cancer also exerts a profound psychosocial impact (Bertagnolli *et al.*, 2017). It places emotional and psychological burdens on patients, their families, and caregivers, affecting their quality of life. On a global scale, cancer represents a pressing public health challenge that spans both developed and developing countries. Its incidence is expected to rise, particularly in low- and middle-income nations where resources for cancer care are limited. This highlights the urgent need for accessible and effective cancer prevention and treatment strategies, particularly as many cancer cases are preventable through lifestyle changes, early detection, and vaccination programs (Wilkerson *et al.*, 2017).

The burden of cancer on a global scale is a complex and pressing issue that underscores the urgency of advancing cancer research through approaches like ethnopharmacology (Guinney *et al.*, 2017). Cancer represents a formidable challenge to public health and a substantial burden in multiple dimensions:

(i) *High Incidence and Mortality*: Cancer is one of the prime reasons of death worldwide. Its high incidence and significant mortality rates place an enormous burden on healthcare systems, economies, and societies at large.

(ii) *Diverse Cancer Types*: The spectrum of cancer encompasses numerous types, each with its unique characteristics and treatment challenges. This diversity further complicates efforts to combat the disease (Seyednasrollah *et al.*, 2017).

(iii) *Economic Impact*: The economic burden of cancer is substantial. It encompasses not only the direct costs of cancer diagnosis and treatment but also indirect costs, including lost productivity due to illness and caregiving.

(iv) *Healthcare Resource Utilization*: Cancer places heavy demands on healthcare resources, including diagnostic equipment, medications, healthcare

personnel, and hospital facilities. The cost of cancer care can be prohibitive in many regions (Grossman *et al.*, 2016).

(v) *Health Disparities*: Disparities in cancer care and outcomes exist globally. Access to early detection, effective treatments, and supportive care varies widely, leading to unequal outcomes for different populations.

(vi) *Psychosocial Impact*: The burden of cancer extends beyond the physical and economic realms. It also has a significant psychosocial impact on patients, their families, and caregivers, often leading to emotional distress and reduced quality of life (Heath *et al.*, 2021).

(vii) *Preventable Cases*: Many cancer cases are preventable through lifestyle changes, early detection, and vaccination programs. This underscores the importance of cancer prevention and awareness campaigns (Jemal *et al.*, 2017).

Limitations of modern cancer treatments:

Modern cancer treatments, while undoubtedly significant in improving patient outcomes, have certain limitations that make the exploration of alternative approaches like traditional healing practice with modern pharmacognosy. Followings are some of the key limitations of modern cancer treatments:

(a) *Toxicity*: Many chemotherapy drugs and radiation therapies have substantial toxic effects on the body. They can damage healthy cells and tissues along with cancer cells, leading to a range of side effects that affect a patient's quality of life (De Moor *et al.*, 2013).

(b) *Drug Resistance*: Cancer cells often develop resistance to chemotherapy and targeted therapies, rendering these treatments ineffective over time. This limits the long-term success of many modern cancer treatments.

(c) *Narrow Spectrum*: Some modern treatments are highly specific to certain types of cancer or genetic mutations. This limits their applicability to a broader range of cancers (Burstein *et al.*, 2017).

(d) *High Cost*: Modern cancer treatments, especially immunotherapies and targeted therapies, can be prohibitively expensive, creating disparities in access to care and straining healthcare systems.

(e) *Limited Efficacy*: Despite advancements, certain cancers remain highly resistant to treatment, and for some patients, treatment options are limited (Gordon *et al.*, 2017).

(f) *Adverse Effects on Quality of Life*: Cancer treatments often have noticable ill effects, which can reduce a patient's quality of life and limit their ability to carry on with normal activities.

(g) *Long-Term Health Effects*: Some cancer treatments, particularly radiation therapy and certain chemotherapies, can have long-term health consequences, including an increased risk of secondary cancers.

(h) *Inadequate for Advanced Stages*: For many advanced-stage cancers, modern treatments may only provide limited extensions of life, and a cure may not be achievable (Schoen *et al.*, 2011).

(i) *Access and Equity*: Access to cutting-edge modern cancer treatments is not uniform across regions and populations, leading to disparities in outcomes and survival rates.

(j) *Patient Preferences*: Some patients may prefer complementary or alternative therapies that align more closely with their beliefs and values, making patient-centered care a challenge (Kankeu *et al.*, 2013).

Long-term health effects, such as an increased risk of secondary cancers, are a concern associated with certain modern treatments. Moreover, for advanced-stage cancers, modern treatments may only offer modest extensions of life without the possibility of a cure.

Access to cutting-edge cancer treatments is far from uniform across regions and populations, resulting in disparities in outcomes and survival rates. The diverse preferences of cancer patients, who may lean towards complementary or

alternative therapies, complicate the delivery of patient-centered care (Fitch *et al.*, 2021).

Need for innovative approaches:

The need for innovative approaches in the context of "Ethnopharmacology and Cancer: Bridging traditional healing practice with modern pharmacognosy" is driven by several compelling factors, primarily associated with the formidable challenges posed by cancer (Currow and Aranda, 2016). These challenges demand fresh, forward-thinking strategies to improve cancer prevention, treatment, and care:

(i) *Growing Cancer Burden*: Cancer's global burden is on the rise, with an increasing number of cases and cancer-related deaths. The need for innovative approaches is amplified by the urgency to address this escalating public health crisis.

(ii) *Treatment Limitations*: Modern cancer treatments, while effective, have limitations, including toxicity, drug resistance, and high costs. Innovative approaches are needed to overcome these limitations and enhance the effectiveness of cancer therapies (Iragorri *et al.*, 2021).

(iii) *Health Disparities*: Disparities in cancer care and outcomes persist, creating inequalities in survival rates. Innovative approaches should aim to reduce these disparities and make advanced cancer care more accessible to all, irrespective of socioeconomic and geographical factors.

(iv) *Patient-Centered Care*: Patients often seek more personalized and patient-centered care. Innovative approaches must consider the individual's preferences and values, including the exploration of complementary and alternative therapies like ethnopharmacology (Altice *et al.*, 2017).

(v) *Cultural Sensitivity*: Recognizing the diverse cultural backgrounds of patients is paramount. Innovative approaches, like the integration of traditional healing practices, ensure that cancer care respects and incorporates cultural traditions and beliefs.

(v) *Emerging Therapeutic Avenues*: Advances in technology and scientific research have opened up new therapeutic avenues for cancer treatment. Ethnopharmacology provides a unique bridge between ancient wisdom and modern science, tapping into natural remedies for potential breakthroughs (Pearce *et al.*, 2019).

(vii) *Prevention and Early Detection*: Innovative approaches are needed for cancer prevention and early detection, reducing the need for aggressive treatments. Ethnopharmacological research may uncover natural compounds with preventative properties.

(viii) *Respecting Biodiversity*: The need to respect and preserve biodiversity is essential. Ethnopharmacology supports responsible harvesting and cultivation of medicinal plants, promoting sustainable practices (Mehnert, 2011).

(ix) *Cost-Effective Solutions*: With the rising cost of healthcare, innovative approaches should also prioritize cost-effective solutions that make cancer care more affordable for individuals and healthcare systems.

(x) *Global Collaboration*: Collaboration between different disciplines and across diverse cultures is increasingly essential. Innovative approaches encourage partnerships between traditional healers, researchers, healthcare professionals, and policymakers to tackle the global cancer challenge collectively (Girgis *et al.*, 2013).

Bridging the Gap: *Ethnopharmacology and Cancer*: In essence, ethnopharmacological research presents an avenue for transformative advancements in cancer treatment. By exploring the potential of traditional remedies, researchers aim to unlock innovative, accessible, and culturally relevant cancer therapies (Mols *et al.*, 2020). This approach leverages the wisdom of indigenous cultures and ancient healing practices, synergizing them with modern science to confront one of the most challenging diseases of our time: cancer. The potential benefits are extensive, encompassing novel drug discovery, sustainable practices, and improved patient outcomes (Mujahid *et al.*, 2011).

The potential of ethnopharmacological research in cancer treatment is an exciting and transformative frontier within the context of "Ethnopharmacology and Cancer: Bridging traditional healing practice with modern pharmacognosy." This approach represents a gateway to promising advancements in the quest for more effective, culturally sensitive, and holistic cancer treatments. Ethnopharmacology leverages a multitude of advantages, foremost among them being the exploration of biodiversity found in indigenous regions. Traditional knowledge has for centuries identified a vast array of plant species with potential medicinal properties (Mendelssohn and Yom-Tov, 1999). By subjecting these traditional remedies to rigorous scientific validation, researchers have the opportunity to unearth novel bioactive compounds with profound anti-cancer potential. One of the most captivating prospects is the potential for novel drug discovery. Ethnopharmacological research offers the possibility of unearthing entirely new drugs or leads for cancer treatment, overcoming drug resistance, and providing more potent and effective treatment options. Sustainability and conservation are integral to this approach. Ethnopharmacology places a strong emphasis on responsible practices in harvesting and cultivating medicinal plants, ensuring the long-term availability of these resources while preserving biodiversity and safeguarding the environment (Lev, 2006).

The integration of modern knowledge and traditional healing practices into modern cancer care, as highlighted in the context of "Ethnopharmacology and Cancer: Bridging traditional healing practice with modern pharmacognosy," has produced remarkable success stories. These instances illustrate the transformative potential of such integrations in enhancing healthcare outcomes (Azaizeh *et al*., 2006). One striking example is Vincristine, a vital chemotherapy drug used in treating leukemia and lymphoma. It originated from the Madagascar periwinkle, a plant recognized for its medicinal properties through indigenous knowledge. The *Camptotheca acuminata* tree's bark and stem, acknowledged for its medicinal potential through traditional wisdom, led to the identification of Camptothecin, another compound employed in modern cancer therapy (Azaizeh *et al*., 2010). The integration of these indigenous findings into modern medicine exemplifies the value of preserving cultural heritage and respecting the wealth of knowledge held by diverse communities. It underscores the transformative potential of bridging ancient wisdom with contemporary scientific rigor, contributing to more effective and culturally sensitive cancer treatments. These examples underscore the significant contributions of indigenous knowledge to the development of innovative therapies in the fight against cancer and other diseases (Ben-Arye and Samuels, 2015).

Modern Pharmacognosy: Unlocking Nature's Potential:

Pharmacognosy, within the context of "Ethnopharmacology and Cancer: Bridging traditional healing practice with modern pharmacognosy," is a field of study that focuses on the comprehensive exploration of natural sources, particularly medicinal plants, to identify, isolate, and study bioactive compounds with potential therapeutic properties (Saad *et al*., 2005). It involves the extraction, purification, and characterization of these compounds from various sources, including plants, fungi, and marine organisms (Ghorbani, 2014). The primary significance of pharmacognosy in this context lies in its role as a bridge between traditional healing practices and modern medicine, specifically in the context of cancer research and treatment. Following is a breakdown of its definition and significance:

Pharmacognosy involves the systematic investigation of natural products to understand their chemical composition, biological activities, and potential applications in medicine. It encompasses the study of plant-based medicines, herbal remedies, and traditional healing practices that have been used by indigenous cultures for centuries. Pharmacognosists aim to identify the

active compounds responsible for the therapeutic effects of these natural products and, in the context of cancer, to explore their potential in the development of new cancer treatments (Ehrenreich and English, 2010).

Significance:

The significance of pharmacognosy extends to drug discovery and development, playing a pivotal role in identifying bioactive compounds from natural sources that possess the potential to be harnessed into new drugs. In the context of cancer, this can result in the discovery of powerful anti-cancer agents (Solecki, 1975). The discipline's techniques enable the isolation and identification of these bioactive compounds, which is paramount in the quest to develop potential chemotherapeutic agents and cancer-fighting substances. The innovative treatments that result from pharmacognosy not only offer expanded options for cancer patients but also have the potential to enhance therapeutic efficacy and reduce the side effects that often accompany traditional chemotherapies (Booker *et al*., 2012).

Pharmacognosy emphasizes the importance of sustainable practices in the cultivation and harvesting of medicinal plants, contributing to the preservation of biodiversity and the environment. This sustainability is crucial for ensuring a continuous and ethical supply of resources for cancer research and treatment. Moreover, pharmacognosy fosters cultural sensitivity by recognizing and incorporating the preferences, beliefs, and traditions of patients from diverse cultural backgrounds (Manandhar, 1995). This patient-centered approach aligns healthcare with individual values and ensures that cancer care is inclusive and relevant to various cultural contexts. In essence, pharmacognosy stands as a cornerstone of progress in the field of ethnopharmacology and cancer treatment. Its definition encompasses the rigorous study of natural sources, and its significance lies in its role as a bridge, a vehicle for innovation, and a guardian of cultural heritage (Sahoo *et al*., 2010). This discipline actively contributes to the development of more effective, culturally sensitive, and sustainable cancer therapies while paying homage to the wealth of traditional wisdom held by indigenous communities (Madhuri and Pandey, 2008).

Technologies and methodologies in modern pharmacognosy:

Modern pharmacognosy relies on a range of advanced technologies and methodologies to explore the bioactive compounds derived from natural sources and their potential applications in cancer research and treatment (Sivalokanathan *et al*., 2005). These technologies and methodologies are pivotal for enhancing the efficiency and precision of pharmacognosy research:

(a) *High-Performance Liquid Chromatography* (*HPLC*): HPLC (high-performance liquid chromatography) is an advanced analytical method that is utilized in pharmacognosy to separate, identify, and measure complex mixtures of bioactive substances. It is particularly useful for identifying the presence and concentration of potentially anticancer compounds in natural sources (Pihlak *et al*., 2014).

(b) *Mass Spectrometry* (*MS*): Mass spectrometry is employed to identify and characterize individual compounds in a mixture based on their mass-to-charge ratio. It is indispensable for identifying and elucidating the structures of bioactive compounds derived from natural sources (Rosangkima and Prasad, 2004).

(c) *Nuclear Magnetic Resonance* (*NMR*) *Spectroscopy*: NMR spectroscopy is used to study the molecular structures and properties of bioactive compounds. It is crucial for confirming the identity and purity of isolated compounds.

(d) *DNA Barcoding*: DNA barcoding is a molecular biology technique used to identify and authenticate plant species. This method is essential in ensuring the accurate identification of medicinal plants and their bioactive compounds (Ovadje *et al*., 2015).

(e) *Bioassays*: Bioassays involve testing the

biological activity of natural compounds. These assays help researchers evaluate the potential anti-cancer properties of compounds and understand their mechanisms of action (Bray *et al*., 2013).

(f) *Metabolomics*: Metabolomics is the comprehensive study of the small molecules (metabolites) present in biological samples. It aids in understanding the metabolic changes induced by bioactive compounds in cancer cells, contributing to the development of cancer treatments (Jemal *et al*., 2011).

(g) *Chemoinformatics*: Chemoinformatics involves the use of computational techniques to analyze and model the chemical properties of bioactive compounds. It plays a crucial role in virtual screening and rational drug design.

(h) *Pharmacokinetics and Pharmacodynamics (PK/PD)*: PK/PD studies help assess how bioactive compounds are absorbed, distributed, metabolized, and eliminated by the body. Understanding the pharmacokinetics and pharmacodynamics of these compounds is essential for optimizing their use in cancer treatment (Siegel *et al*., 2012).

(i) *Biomarker Discovery*: Modern pharmacognosy also incorporates molecular techniques to discover and validate cancer biomarkers. These biomarkers are vital for early cancer detection, prognosis, and monitoring treatment responses.

(j) *Omics Technologies*: Omics technologies, including genomics, proteomics, and transcriptomics, are used to study the genetic, protein, and gene expression profiles associated with cancer. This information aids in understanding the molecular mechanisms of cancer and identifying potential therapeutic targets (DiMasi *et al*., 2016).

Modern pharmacognosy leverages an array of advanced technologies and methodologies to unlock the potential of bioactive compounds derived from natural sources and apply them to the realm of cancer research and treatment (Zhang *et al*., 2009). These cutting-edge tools are indispensable for optimizing the efficiency and precision of pharmacognosy research. HPLC plays a pivotal role in separating, identifying, and quantifying complex mixtures of bioactive compounds. Mass Spectrometry (MS) steps in to precisely identify and characterize individual compounds based on their mass-to-charge ratio. NMR Spectroscopy is employed to scrutinize molecular structures and confirm the identity of isolated compounds. DNA barcoding, a molecular biology technique, ensures the accurate identification of medicinal plants, an essential step in pharmacognosy (Zhang *et al*., 2012). Bioassays gauge the biological activity of natural compounds, shedding light on their anti-cancer potential and mechanisms of action. Metabolomics scrutinize the small molecules within biological samples, offering insights into the metabolic changes induced by bioactive compounds in cancer cells (Trunzer *et al*., 2009). Chemoinformatics deploys computational techniques for chemical analysis, playing a pivotal role in rational drug design and virtual screening. Pharmacokinetics and Pharmacodynamics (PK/PD) studies unravel how bioactive compounds are processed within the body, vital for optimizing their use in cancer treatment (De Voss *et al*., 1997). Biomarker discovery harnesses molecular techniques to identify and validate cancer biomarkers, which are pivotal for early detection, prognosis, and treatment monitoring. Omics technologies, such as genomics, proteomics, and transcriptomics, provide a comprehensive view of the genetic and molecular underpinnings of cancer, illuminating potential therapeutic targets. Data analytics and artificial intelligence guide the analysis of vast datasets, predict compound activities, and expedite drug discovery. Finally, biological target identification identifies specific molecular targets within cancer cells that bioactive compounds can engage with, paving the way for the development of precision cancer therapies (Zhang *et al*., 1998). These technologies and methodologies collectively amplify the potential of pharmacognosy, unearthing bioactive compounds and innovative advancements for the treatment of cancer. This

integration epitomizes the fusion of ancient healing wisdom with contemporary scientific rigor, forging a potent synergy in the battle against cancer (Silverman and Holladay, 2014).

Role of ethnopharmacological insights in pharmacognosy:

The role of ethnopharmacological insights in pharmacognosy exemplifies the synergy between traditional healing practices and modern science. It streamlines the process of identifying, isolating, and characterizing bioactive compounds from natural sources while respecting cultural traditions and contributing to sustainable practices (Bouska *et al*., 1997). This approach not only enriches the field of pharmacognosy but also offers the potential for more effective, culturally sensitive, and holistic cancer treatments, aligning with the core objectives of "bridging traditional healing practice with modern pharmacognosy" in the fight against cancer (Braeckman *et al*., 1989).

One of the primary roles of ethnopharmacological insights is the identification of medicinal plants. Indigenous communities have developed an intimate understanding of their local flora over generations, recognizing plants with potential therapeutic properties. This knowledge serves as a vital compass for pharmacognosy researchers, directing them to specific plant species that may harbor bioactive compounds with the potential to combat cancer (Dierks *et al*., 1998; Li *et al*., 2010).

Traditional healing practices and remedies hold another key role. They serve as leads for pharmacognosy investigations. Researchers can delve into these time-tested remedies to isolate and study the bioactive compounds responsible for their therapeutic effects. This not only expedites the drug discovery process but also ensures that promising natural sources are explored, potentially leading to the development of new cancer treatments. Cultural significance is a crucial aspect of ethnopharmacological insights (White and McCarthy, 1986). These insights emphasize the cultural context surrounding the use of specific plants and remedies. Understanding this context is vital for developing modern pharmaceuticals that respect and incorporate cultural traditions. It ensures that healthcare is not only effective but also culturally sensitive and relevant to the communities it serves. Sustainability practices, often embedded in indigenous knowledge, play an essential role in the preservation of biodiversity. Many indigenous communities have sustainable harvesting and cultivation practices for medicinal plants, contributing to the long-term availability of these resources for pharmacognosy research (Duquette *et al*., 1983).

Case Studies: *Ethnopharmacology in Cancer Research*:

There are successful ethnopharmacological approaches that have made noteworthy contributions to cancer treatment. These approaches demonstrate the immense potential of integrating traditional healing practices with modern pharmacognosy in the fight against cancer. followings are some examples of such successful approaches:

(i) *Taxol from the Pacific Yew Tree*: Indigenous knowledge of the Pacific yew tree (*Taxus brevifolia*) has played a significant role in the discovery of a breakthrough cancer treatment. The traditional healing practices have recognized the medicinal value of trees, which guided modern pharmacognosy research. As a result, Taxol, derived from the bark of the Pacific yew tree, has become an essential component in the treatment of various cancers, including ovarian, breast, and lung cancers (Gotoh, 1992).

(ii) *Artemisinin from Sweet Wormwood*: Indigenous Chinese medicine used sweet wormwood (*Artemisia annua*) for centuries to treat fevers. This traditional knowledge eventually led to the discovery of artemisinin, a powerful anti-malarial compound. Recently, it has also shown potential in cancer treatment, demonstrating the versatility of ethnopharmacological insights.

(iii) *Vincristine from Madagascar Periwinkle*: Indigenous knowledge in Madagascar recognized

the medicinal properties of the Madagascar periwinkle (Catharanthus roseus). This led to the isolation of vincristine, a chemotherapy drug used in the treatment of leukemia and lymphoma (Cupp-Vickery and Poulos, 1995).

(iv) *Camptothecin from Camptotheca acuminata*: Traditional knowledge about the *Camptotheca acuminata* tree led to the discovery of camptothecin, a compound with anti-cancer properties. This compound has been employed in modern cancer therapy.

These successful ethnopharmacological approaches highlight the critical role of customary healing practices in the development of cancer treatments. Indigenous knowledge has served as a valuable guide for modern pharmacognosy research, leading to the identification of bioactive compounds with significant anti-cancer potential (Lewis and Dickins, 2003). These examples underscore the importance of recognizing the wealth of wisdom held by indigenous communities and the transformative potential of integrating their insights with modern science. This integration not only respects cultural traditions but also offers innovative and effective solutions in the ongoing battle against cancer (Lewis *et al.*, 2004).

Scientific validation and clinical trials:

Scientific validation and clinical trials play a critical role in the development and evaluation of potential cancer treatments derived from traditional healing practices and pharmacognosy research. These processes are essential to ensure the safety and efficacy of new therapies:

(a) *Scientific Validation*: Scientific validation involves rigorous laboratory testing to confirm the bioactivity of compounds derived from natural sources, such as medicinal plants (Buriani *et al.*, 2012). This validation typically includes *in vitro* studies where researchers assess the effects of the compounds on cancer cells. The goal is to establish that the compounds have the potential to inhibit cancer cell growth, induce apoptosis (cell death), or disrupt cancer-related pathways.

(b) *Preclinical Studies*: Before advancing to clinical trials, compounds must undergo preclinical studies. These studies involve testing the potential treatments in animal models, often rodents, to evaluate their safety and effectiveness. Researchers examine the compound's pharmacokinetics, toxicity, and overall impact on the cancer in vivo (Bye *et al.*, 1995).

(c) *Clinical Trials*: Clinical trials are the gold standard for evaluating the safety and efficacy of potential cancer treatments. These trials are conducted in phases, typically from Phase I to Phase III, and involve human participants. Phase I trials assess the safety of the treatment, Phase II trials evaluate its effectiveness, and Phase III trials compare the new therapy to existing standard therapies. Clinical trials provide crucial data on the treatment's impact on patients and guide decisions on whether it should be approved for widespread use.

(d) *Biological and Molecular Markers*: Biomarkers are used in clinical trials to assess treatment responses. These markers may include specific genes, proteins, or other molecules that indicate how the treatment is affecting the cancer. Monitoring biomarkers allows researchers to tailor treatment to individual patients and develop targeted therapies (Carrera-Bastos *et al.*, 2011).

(e) *Randomized Controlled Trials* (*RCTs*): RCTs are considered the most robust form of clinical trials. Patients are randomly assigned to either receive the experimental therapy or a control (e.g. a standard therapy or a placebo). RCTs are essential for determining the true efficacy of a treatment while minimizing biases.

(f) *Adverse Event Monitoring*: Clinical trials also focus on monitoring and documenting any adverse events or side effects associated with the treatment. This information is critical for assessing the safety and tolerability of the therapy (Carvalho *et al.*, 2011).

(g) *Regulatory Approval*: After successful clinical trials, treatments must gain regulatory approval

from health authorities, like U.S. FDA or the (EMA), before they can be used in mainstream healthcare.

(h) *Post-Marketing Surveillance*: Even after regulatory approval, treatments continue to be monitored in the real-world setting through post-marketing surveillance. This ongoing evaluation helps identify rare or long-term side effects and further informs treatment guidelines (Casselman and Heinrich, 2011).

Scientific validation and clinical trials are vital steps in the journey from traditional healing practices and ethnopharmacology research to the development of new cancer treatments. They ensure that potential therapies are rigorously tested for both safety and efficacy, providing patients with the best possible care while maintaining the highest standards of medical practice. This integration of science and tradition exemplifies the spirit of "bridging traditional healing practice with modern pharmacognosy" in the context of cancer treatment (Charles *et al*., 2011).

Challenges and Ethical Considerations:

Several ethical issues surround ethno-pharmacological research. These issues require careful consideration to ensure that the research respects the rights, values, and well-being of indigenous communities and traditional healers:

(i) *Respect for Cultural Knowledge*: Ethnopharmacological research is essential to respect intellectual property rights of these communities and acknowledge their contributions. Researchers should seek informed consent and collaborate with local experts to ensure that the research process honors cultural practices and values (Chevallier, 2000).

(ii) *Prior Informed Consent* (*PIC*): Obtaining PIC from indigenous communities is crucial. Researchers must clearly communicate the research objectives and potential outcomes to these communities. Communities should have the opportunity to provide or withhold consent, and the terms of any collaboration should be fair and mutually agreed upon.

(iii) *Benefit Sharing*: Ethical concerns arise when commercial products or treatments are developed based on indigenous knowledge. Fair benefit-sharing mechanisms should be established to ensure that indigenous communities receive a portion of the benefits derived from the commercialization of products or therapies. This can include financial compensation, healthcare support, or other resources (Chotchoungchatchai *et al*., 2012).

(iv) *Cultural Appropriation*: Researchers must be cautious to avoid cultural appropriation, which involves the unauthorized use of cultural elements for personal or commercial purposes. It is important to engage respectfully with indigenous cultures and seek their approval when utilizing their traditional knowledge.

(v) *Protection of Indigenous Rights*: Ethnopharmacological research should align with international conventions and agreements, such as the United Nations Declaration on the Rights of Indigenous Peoples. These documents emphasize protection of indigenous rights, including the right to self-determination, cultural preservation, and participation in decision-making processes (Cordell, 2011).

(vi) *Preservation of Biodiversity*: Research should consider the impact of plant collection on local biodiversity. It's ethically important to ensure the sustainable use of medicinal plants and promote practices that do not harm the environment or endanger species.

(vii) *Privacy and Confidentiality*: Indigenous knowledge may contain sensitive or confidential information. Researchers must maintain the privacy and confidentiality of the information shared by traditional healers and indigenous communities (Darvishzadeh-Mahani *et al*., 2012).

(viii) *Community-Based Research*: Emphasizing community-based research approaches can help ensure that the research process is more inclusive and respectful of community needs and concerns.

(ix) *Ethical Review Boards*: Ethnopharmacological research should undergo ethical review by

institutional review boards (IRBs) or ethics committees. These boards can help ensure that research protocols adhere to ethical principles and international standards (Arbour and Cook, 2006).

(x) *Long-Term Relationships*: Building long-term and mutually beneficial relationships with indigenous communities is essential. This approach fosters trust and collaboration, allowing for meaningful and ethical research partnerships.

Ethical issues in ethnopharmacological research highlight the need to approach traditional knowledge with sensitivity, respect, and a commitment to fair collaboration (Brant Castellano, 2004).

Future Directions and Collaboration:

Future directions and fostering collaboration between traditional healers and scientists holds immense promise for the advancement of cancer treatment. Here are key considerations for the potential for collaborative research:

(a) *Combining Traditional Wisdom with Scientific Rigor*: Collaborative research can harness the strengths of traditional healers' profound knowledge of medicinal plants and healing practices and the scientific rigor of modern pharmacognosy. By combining these two approaches, researchers can identify, validate, and develop new cancer treatments more efficiently (Campbell, 2014).

(b) *Diverse Sources of Knowledge*: Traditional healers offer a wealth of knowledge about local and regional plants, some of which may hold untapped potential for cancer therapy. Collaborative research ensures that this diversity of knowledge is leveraged (Fajreldin, 2010).

(c) *Cross-Cultural Understanding*: Collaborative research fosters cross-cultural understanding and mutual respect. Traditional healers and scientists come to appreciate each other's worldviews, leading to a richer and more respectful exchange of knowledge.

(d) *Benefit-Sharing and Empowerment*: Collaborative research models often include benefit-sharing mechanisms that empower indigenous communities and traditional healers. This can involve financial compensation, capacity-building programs, and healthcare support, ensuring that benefits are equitably shared (Justo, 2004).

(e) *Sustainability Practices*: Traditional healers often emphasize sustainable harvesting and cultivation of medicinal plants. Collaborative research can promote these practices, contributing to the preservation of biodiversity and the environment.

(f) *Cultural Awareness*: Scientists gain a deeper cultural awareness through collaboration, which is vital for respecting the values and practices of indigenous communities. This understanding promotes a more inclusive and sensitive research approach (Justo, 2012).

(g) *Improved Patient-Centered Care*: Collaborative research ensures that cancer treatments are developed with a patient-centered focus. Patients from diverse cultural backgrounds can benefit from therapies that align with their beliefs and traditions, enhancing the overall quality of healthcare.

(h) *Scientific Validation*: Collaborative research allows for the scientific validation of traditional remedies. Traditional healers' knowledge is used to identify potential treatments, and scientific research is employed to validate their effectiveness and safety (Montenegro and Stephens, 2006).

(i) *Patient Trust*: Patients often trust treatments rooted in their cultural heritage. Collaborative research leads to the development of therapies that are not only effective but also culturally relevant, which enhances patient trust and engagement.

(j) *Innovative Approaches*: Collaboration encourages the exploration of innovative approaches to cancer treatment, combining the best of both traditional and modern worlds. This can lead to the development of unique therapies with improved efficacy (Schnarch, 2004).

Conclusion

In conclusion, the promise of ethnopharmacology in improving cancer care is grounded in the wealth of untapped potential found in traditional remedies. By bridging traditional healing practices with modern pharmacognosy, researchers and healthcare practitioners aim to unlock innovative solutions that enhance the effectiveness of cancer treatment, ensure cultural relevance, and make healthcare more accessible and sustainable on a global scale. The fusion of traditional wisdom with contemporary science holds great promise for advancing cancer care and bringing relief to patients worldwide.

The promise of ethnopharmacology in advancing cancer care, as explored in the context of "Ethnopharmacology and Cancer: Bridging traditional healing practice with modern pharmacognosy," is both significant and multifaceted. One of its most compelling aspects lies in the vast potential for discovering novel bioactive compounds hidden within traditional remedies. These remedies, often derived from natural sources, have been passed down through generations and represent a largely unexplored treasure trove of therapeutic agents. By integrating the traditional wisdom of these practices with the scientific rigor of modern pharmacognosy, researchers hold the promise of unearthing unique compounds that could redefine the landscape of cancer treatment. Moreover, ethnopharmacology has the potential to enhance the efficacy of cancer treatments. Traditional remedies are often characterized by the use of multiple plants or compounds, resulting in a synergy that can boost treatment effectiveness. This synergy can potentially reduce the side effects associated with higher doses of single drugs, making cancer therapy not only more potent but also more tolerable for patients.

References

AACR Project GENIE Consortium (2017) AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov. 7(8): 818-831.

Adams M, Alther W, Kessler M, Kluge M and Hamburger M. (2011a) Malaria in the renaissance: remedies from European herbals from the 16th and 17th century. J Ethnopharmacol. 133(2): 278-288.

Adams M, Gschwind S, Zimmermann S, Kaiser M and Hamburger M. (2011b) Renaissance remedies: antiplasmodial protostane triterpenoids from *Alisma plantago-aquatica* L. (Alismataceae). J Ethnopharmacol. 135(1): 43-47.

Aggarwal BB, Prasad S, Reuter S, Kannappan R, Yadev VR, Park B, Kim JH, Gupta SC, Phromnoi K, Sundaram C, Prasad S, Chaturvedi MM and Sung B. (2011) Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach. Curr Drug Targets 12(11): 1595-1653.

Altice CK, Banegas MP, Tucker-Seeley RD and Yabroff KR. (2017) Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 109(2): djw205.

Anonymous (1879) The experimental study of disinfectants. Lancet 114(2928): 558-559.

Arbour L and Cook D. (2006) DNA on loan: issues to consider when carrying out genetic research with aboriginal families and communities. Community Genet. 9(3): 153-160.

Azaizeh H, Saad B, Cooper E and Said O. (2010) Traditional Arabic and Islamic medicine, a re-emerging health aid. Evid Based Complement Alternat Med. 7(4): 419-424.

Azaizeh H, Saad B, Khalil K and Said O. (2006) The state of the art of traditional Arab herbal medicine in the Eastern region of the Mediterranean: a review. Evid Based Complement Alternat Med. 3(2): 229-235.

Balick MJ. (1990) Ethnobotany and the identification of therapeutic agents from the rainforest. Ciba Found Symp. 154: 22-31.

Ben-Arye E and Samuels N. (2015) Homeopathy on the crossroads of traditional and integrative medicine in the Middle-East. J Med Person 13(1): 65-71.

Berkes F, Colding J and Folke C. (2000) Rediscovery of traditional ecological knowledge as adaptive management. Ecol Appl. 10(5): 1251-1262.

Bertagnolli MM, Sartor O, Chabner BA, Rothenberg ML, Khozin S, Hugh-Jones C, Reese DM and Murphy MJ. (2017) Advantages of a truly open-access data-sharing model. N Engl J Med. 376(12): 1178-1181.

Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M and Tracey I. (2011) The effect of treatment expectation on drug efficacy: imaging

the analgesic benefit of the opioid remifentanil. Sci Transl Med. 3(70): 70ra14.

Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A and Maitra A. (2007) Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnol. 5: 3.

Booker A, Johnston D and Heinrich M. (2012) Value chains of herbal medicines – research needs and key challenges in the context of ethnopharmacology. J Ethnopharmacol. 140(3): 624-633.

Bouska JJ, Bell RL, Goodfellow CL, Stewart AO, Brooks CD and Carter GW. (1997) Improving the *in vivo* duration of 5-lipoxygenase inhibitors: application of an *in vitro* glucuronosyltransferase assay. Drug Metab Dispos. 25(9): 1032-1038.

Braeckman RA, Granneman GR, Rubin PR and Kesterson JW. (1989) Pharmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after single oral administration in man. J Clin Pharmacol. 29: A22.

Brant Castellano M. (2004) Ethics of aboriginal research. J Abor Health 1: 98-114.

Bray F, Ren JS, Masuyer E and Ferlay J. (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132(5): 1133-1145.

Bristow F, Nettleton C and Stephens C. (2003) Utz W'achil: Health and wellbeing among Indigenous peoples. Health Unlimited, pp. 35.

Browner CH, Montellano BRO and Rubel AJ. (1988) A methodology for cross-cultural ethnomedical research. Curr Anthropol. 29(5): 681-702.

Buenz EJ, Schnepple DJ, Bauer BA, Elkin PL, Riddle JM and Motley TJ. (2004) Techniques: bioprospecting historical herbal texts by hunting for new leads in old tomes. Trends Pharmacol Sci. 25(9): 494-498.

Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X, Simmonds MS, Carrara M, Tejedor N, Lucio-Cazana J and Hylands PJ. (2012) Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol. 140(3): 535-544.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ and Dizon DS. (2017) Clinical cancer advances 2017: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 35(12): 1341-1367.

Bye R, Linares E and Estrada E. (1995) Biological diversity of medicinal plants in Mexico. In: Phytochemistry of medicinal plants, (eds.) Arnason J.T., Mata R. and Romeo J.T., Plenum Press, New York, pp. 65-82.

Campbell TD. (2014) A clash of paradigms? Western and indigenous views on health research involving aboriginal peoples. Nurse Res. 21(6): 39-43.

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG and Nutt DJ. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA. 109(6): 2138-2143.

Carrera-Bastos P, Fontes M, O'Keefe JH, Lindeberg S, Cordain L. The western diet and lifestyle and diseases of civilization. Res Rep Clin Cardiol. 2011;2:15-35.

Carvalho CA, Fernandes KM, Matta SL, Silva MB, Oliveira LL and Fonseca CC. (2011) Evaluation of antiulcerogenic activity of aqueous extract of Brassica oleracea var. capitata(cabbage) on Wistar rat gastric ulceration. Arq Gastroenterol. 48(4): 276-282.

Casselman I and Heinrich M. (2011) Novel use patterns of salvia divinorum: unobtrusive observation using YouTube®. J Ethnopharmacol. 138(3): 662-667.

Charles PD, Ambigapathy G, Geraldine P, Akbarsha MA and Rajan KE. (2011) *Bacopa monniera* leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: implications in memory formation. J Ethnopharmacol. 134(1): 55-61.

Chevallier A. (2000) Encyclopedia of herbal medicine. The definitive reference to 550 herbs and remedies for common ailments. DK Publishing, New York.

Chotchoungchatchai S, Saralamp P, Jenjittikul T, Pornsiripongse S and Prathanturarug S. (2012) Medicinal plants used with Thai traditional medicine in modern healthcare services: a case study in Kabchoeng Hospital, Surin Province, Thailand. J Ethnopharmacol. 141(1): 193-205.

Cordell GA. (20110 Sustainable medicines and global health care. Planta Med. 77(11): 1129-1138.

Cupp-Vickery JRb and Poulos TL. (1995) Structure of cytochrome P450eryF involved in erythromycin biosynthesis. Nat Struct Biol. 2(2): 144-153.

Currow D and Aranda S. (2016) Financial toxicity in clinical care today: a "menu without prices". Med J Aust. 204(11): 397.

Darvishzadeh-Mahani F, Esmaeili-Mahani S, Komeili G, Sheibani V and Zare L. (2012) Ginger (*Zingiber*

officinale Roscoe) prevents the development of morphine analgesic tolerance and physical dependence in rats. J Ethnopharmacol. 141(3): 901-907.

de Albuquerque UP and de Oliveira RF. (2007) Is the use-impact on native caatinga species in Brazil reduced by the high species richness of medicinal plants? J Ethnopharmacol. 113(1): 156-170.

de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M and Rowland JH. (2013) Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 22(4): 561-570.

De Voss JJ, Sibbesen O, Zhang Z and Ortiz de Montellano PR. (1997) Substrate docking algorithms and prediction of the substrate specificity of cytochrome $P450_{cam}$ and its L244A mutant. J Am Chem Soc. 119(24): 5489-5498.

Dierks EA, Zhang Z, Johnson EF and De Montellano PR. (1998) The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant. J Biol Chem. 273(36): 23055-23061.

DiMasi JA, Grabowski HG and Hansen RW. (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 47: 20-33.

Duquette PH, Erickson RR and Holtzman JL. (1983) Role of substrate lipophilicity on the N-demethylation and type I binding of 3-O-alkylmorphine analogs. J Med Chem. 26(10): 1343-1348.

Ehrenreich B and English D. Witches, midwives, and nurses: A history of women healers. Cuny Feminist Press, pp. 48.

Elisabetsky E. (1991) Sociopolitical, economical, and ethical issues in medicinal plant research. J Ethnopharmacol. 32(1-3): 235-239.

Ellen, Roy F. (1996) Putting plants in their place: Anthropological approaches to understanding the ethnobotanical knowledge of rainforest populations. In: Tropical Rainforest Research — Current Issues: Proceedings of the Conference held in Bandar Seri Begawan (eds.) Edwards D.S., Booth W.E. and Choy S.C., Springer, Dordrecht, Netherlands, pp. 457-465.

Etkin NL. (1988) Ethnopharmacology – biobehavioral approaches in the anthropological study of indigenous medicines. Annu Rev Anthropol. 17(1): 23-42.

Etkin NL. 2001.Perspectives in ethnopharmacology: forging a closer link between bioscience and traditional empirical knowledge. J Ethnopharmacol. 76(2): 177-182.

Etkin NL and Elisabetsky E. (2005) Seeking a transdisciplinary and culturally germane science: the future of ethnopharmacology. J Ethnopharmacol. 100(1-2): 23-26.

Fajreldin V. (2010) Problemas bioéticos de la investigación biomédica con pueblos indígenas de Chile (Bioethical problems in biomedical research with indigenous peoples in Chile, Spanish) Acta Bioethic. 16: 191-197.

Fitch MI, Longo CJ and Chan RJ. (20121) Cancer patients' perspectives on financial burden in a universal healthcare system: analysis of qualitative data from participants from 20 provincial cancer centers in Canada. Patient Educ Couns. 104(4): 903-910.

Ghorbani A. (2014) Clinical and experimental studies on polyherbal formulations for diabetes: current status and future prospective. J Integr Med. 12(4): 336-345.

Giovannini P and Heinrich M. (2009) Xki yoma' (our medicine) and xki tienda (patent medicine)--interface between traditional and modern medicine among the Mazatecs of Oaxaca, Mexico. J Ethnopharmacol. 121(3): 383-399.

Girgis A, Lambert S, Johnson C, Waller A and Currow D. (2013) Physical, psychosocial, relationship, and economic burden of caring for people with cancer: a review. J Oncol Pract. 9(4): 197-202.

Gordon LG, Merollini KMD, Lowe A and Chan RJ. (2017) A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient 10(3): 295-309.

Gotoh O. (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem. 267(1): 83-90.

Green AK, Reeder-Hayes KE, Corty RW, Basch E, Milowsky MI, Dusetzina SB, Bennett AV and Wood WA. (2015) The project data sphere initiative: accelerating cancer research by sharing data. Oncologist 20(5): 464-e20.

Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA and Staudt LM. (2016) Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 375(12): 1109-1112.

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC and Prostate Cancer Challenge DREAM Community (2017) Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a

crowdsourced challenge with open clinical trial data. Lancet Oncol. 18(1): 132-142.

Heath AP, Ferretti V, Agrawal S, An M, Angelakos JC, Arya R, Bajari R, Baqar B, Barnowski JHB, Burt J, Catton A, Chan BF, Chu F, Cullion K, Davidsen T, Do PM, Dompierre C, Ferguson ML, Fitzsimons MS, Ford M, Fukuma M, Gaheen S, Ganji GL, Garcia TI, George SS, Gerhard DS, Gerthoffert F, Gomez F, Han K, Hernandez KM, Issac B, Jackson R, Jensen MA, Joshi S, Kadam A, Khurana A, Kim KMJ, Kraft VE, Li S, Lichtenberg TM, Lodato J, Lolla L, Martinov P, Mazzone JA, Miller DP, Miller I, Miller JS, Miyauchi K, Murphy MW, Nullet T, Ogwara RO, Ortuño FM, Pedrosa J, Pham PL, Popov MY, Porter JJ, Powell R, Rademacher K, Reid CP, Rich S, Rogel B, Sahni H, Savage JH, Schmitt KA, Simmons TJ, Sislow J, Spring J, Stein L, Sullivan S, Tang Y, Thiagarajan M, Troyer HD, Wang C, Wang Z, West BL, Wilmer A, Wilson S, Wu K, Wysocki WP, Xiang L, Yamada JT, Yang L, Yu C, Yung CK, Zenklusen JC, Zhang J, Zhang Z, Zhao Y, Zubair A, Staudt LM and Grossman RL. (2021) The NCI Genomic Data Commons. Nat Genet. 53(3): 257-262.

Heinrich M and Gibbons S. (2001) Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. J Pharm Pharmacol. 53(4): 425-432.

Iragorri N, de Oliveira C, Fitzgerald N and Essue B. (2021) The out-of-pocket cost burden of cancer care—a systematic literature review. Curr Oncol. 28(2): 1216-1248.

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. (2011) Global cancer statistics. CA Cancer J Clin. 61(2): 69-90.

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ and Weir HK. (2017) Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 109(9): djx030.

Justo L. (2004) Participatory research: a way to reduce vulnerability. Am J Bioeth. 4(3): 67-68.

Justo L. (2012) Genética y pueblos originarios, entre tensiones y propuestas. In: Genética y derechos humanos (Genetics and originary peoples, between tensions and proposals, Genetics and Human Rights), (ed.) Penchaszadeh V.B., Buenos Aires, Paidós,pp. 139-175.

Kankeu HT, Saksena P, Xu K and Evans DB. (2013) The financial burden from non-communicable diseases in low- and middle-income countries: a literature review. Health Res Policy Syst. 11(1): 31.

Laird S. (2002) Biodiversity and traditional knowledge: equitable partnerships in practice. Earthscan Publications, London.

Lev E. (2006) Ethno-diversity within current ethno-pharmacology as part of Israeli traditional medicine–a review. J Ethnobiol Ethnomed. 2: 4.

Lewis DF and Dickins M. (2003) Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Metab Rev. 35(1): 1-18.

Lewis DF, Jacobs MN and Dickins M. (2004) Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 9(12): 530-537.

Li CM, Lu Y, Narayanan R, Miller DD and Dalton JT. (2010) Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles. Drug Metab Dispos. 38(11): 2032-2039.

Madhuri S and Pandey G. (2008) Some dietary agricultural plants with anticancer properties. Plant Arch. 8: 13-16.

McDade T, Reyes-García V, Leonard W, Tanner S and Huanca T. (2007) Maternal ethnobotanical knowledge is associated with multiple measures of child health in the Bolivian Amazon. Proc Natl Acad Sci USA. 104: 6134-6139.

Mehnert A. (2011) Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol. 77(2): 109-130.

Mello MM and Wolf LE. (2010) The Havasupai Indian tribe case–lessons for research involving stored biologic samples. N Engl J Med. 363(3): 204-207.

Mendelssohn H and Yom-Tov Y. (1999) Mammalia of Israel. Israel Academy of Sciences and Humanities, Jerusalem.

Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA and AACR Project GENIE Consortium (2018) American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives. JCO Clin Cancer Inform. 2: 1-14.

Moerman DE. (2007) Agreement and meaning: rethinking consensus analysis. J Ethnopharmacol. 112(3): 451-460.

Mols F, Tomalin B, Pearce A, Kaambwa B and Koczwara B. (2020) Financial toxicity and employment status in cancer survivors. A systematic literature review. Support Care Cancer 28(12): 5693-5708.

Montenegro RA and Stephens C. (2006) Indigenous health in Latin America and the Caribbean. Lancet 367(9525): 1859-1869.

Mujahid MS, Janz NK, Hawley ST, Griggs JJ, Hamilton AS, Graff J and Katz SJ. (2011) Racial/ethnic differences

in job loss for women with breast cancer. J Cancer Surviv. 5(1): 102-111.

Ovadje P, Roma A, Steckle M, Nicoletti L, Arnason JT and Pandey S. (2015) Advances in the research and development of natural health products as main stream cancer therapeutics. Evid Based Compl Alt. Med. 2015: 12.

Pardo de Santayana M, Blanco E and Morales R. (2005) Plants known as té in Spain: an ethno-pharmaco-botanical review. J Ethnopharmacol. 98(1-2): 1-19.

Pearce A, Tomalin B, Kaambwa B, Horevoorts N, Duijts S, Mols F, van de Poll-Franse L and Koczwara B. (2019) Financial toxicity is more than costs of care: the relationship between employment and financial toxicity in long-term cancer survivors. J Cancer Surviv. 13(1): 10-20.

Pieroni A and Price L. (2006) Eating and healing. Traditional foods as medicine. The Haworth Press, New York.

Pieroni A, Quave CL, Villanelli ML, Mangino P, Sabbatini G, Santini L, Boccetti T, Profili M, Ciccioli T, Rampa LG, Antonini G, Girolamini C, Cecchi M and Tomasi M. (2004) Ethnopharmacognostic survey on the natural ingredients used in folk cosmetics, cosmeceuticals and remedies for healing skin diseases in the inland Marches, Central-Eastern Italy. J Ethnopharmacol. 91(2-3): 331-344.

Pihlak R, Liivand R, Trelin O, Neissar H, Peterson I, Kivistik S, Lilo K and Jaal J. (2014) Complementary medicine use among cancer patients receiving radiotherapy and chemotherapy: methods, sources of information and the need for counselling. Eur J Cancer Care (Engl) 23(2): 249-254.

Posey DA. (2002) Commodification of the sacred through intellectual property rights. J Ethnopharmacol. 83(1-2): 3-12.

Potter D, Brothers R, Kolacevski A, Koskimaki JE, McNutt A, Miller RS, Nagda J, Nair A, Rubinstein WS, Stewart AK, Trieb IJ and Komatsoulis GA. (2020) Development of CancerLinQ, a health information learning platform from multiple electronic health record systems to support improved quality of care. JCO Clin Cancer Inform. 4: 929-937.

Reyes-García V, McDade T, Vadez V, Huanca T, Leonard WR, Tanner S and Godoy R. (2008) Non-market returns to traditional human capital: nutritional status and traditional knowledge in a native Amazonian society. J Dev Stud. 44(2): 217-232.

Rosangkima G and Prasad SB. (2004) Antitumour activity of some plants from Meghalaya and Mizoram against murine ascites Dalton's lymphoma. Indian J Exp Biol. 42(10): 981-988.

Saad B, Azaizeh H and Said O. (2005) Tradition and perspectives of Arab herbal medicine: a review. Evid Based Complement Alternat Med. 2(4): 475-479.

Sahoo N, Manchikanti P and Dey S. (2010) Herbal drugs: standards and regulation. Fitoterapia81(6): 462-471.

Schnarch B. (2004) Ownership, control, access, and possession (OCAP) or self-determination applied to research: A critical analysis of contemporary First Nations research and some options for First Nations communities. J Aboriginal Health 1: 80-97.

Schoen C, Doty MM, Robertson RH and Collins SR. (2011) Affordable care act reforms could reduce the number of underinsured US adults by 70 percent. Health Aff (Millwood) 30(9): 1762-1771.

Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Kanigel Winner K, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC and Prostate Cancer DREAM Challenge Community (2017) A DREAM challenge to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer. JCO Clin Cancer Inform. 1: 1-15.

Siegel R, Naishadham D and Jemal A. (2012) Cancer statistics, 2012. CA Cancer J Clin. 62(1): 10-29.

Silverman RB and Holladay MW. (2014) Lead discovery and lead modification. In: The organic chemistry of drug design and drug action, (eds.) Silverman R.B. and Holladay M.W., 3rd edn., Academic Press, San Diego, pp. 19-122.

Sivalokanathan S, Ilayaraja M and Balasubramanian MP. (2005) Efficacy of *Terminalia arjuna* (Roxb.) on N-nitrosodiethylamine induced hepatocellular carcinoma in rats. Indian J Exp Biol. 3(3): 264-267.

Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hasset MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, André F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM and AACR Project GENIE Consortium (2020) Characteristics and outcome of *AKT1*^{E17K}-Mutant breast cancer defined through AACR Project GENIE, a clinicogenomic registry. Cancer Discov. 10(4): 526-535.

Solecki RS. (1975) Shanidar IV, a Neanderthal flower burial in northern Iraq. Science 190(4217): 880-881.

Sweeney SM, Hamadeh HK, Abrams N, Adam SJ, Brenner S, Connors DE, Davis GJ, Fiore L, Gawel SH, Grossman

RL, Hanlon SE, Hsu K, Kelloff GJ, Kirsch IR, Louv B, McGraw D, Meng F, Milgram D, Miller RS, Morgan E, Mukundan L, O'Brien T, Robbins P, Rubin EH, Rubinstein WS, Salmi L, Schaller T, Shi G, Sigman CC andSrivastava S. (2023) Challenges to using big data in cancer. Cancer Res. 83(8): 1175-1182.

Ten Kate K and Laird S. (1999) The commercial use of biodiversity: access to genetic resources and benefit-sharing. Routledge. https://doi.org/10.4324/9780429341540.

Thomas E, Vandebroek I, Sanca S and Van Damme P. (2009) Cultural significance of medicinal plant families and species among Quechua farmers in Apillapampa, Bolivia. J Ethnopharmacol. 122(1): 60-67.

Trunzer M, Faller B and Zimmerlin A. (2009) Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC–MS/MS validation. J Med Chem. 52(2): 329-335.

Vandebroek I, Calewaert JB, De jonckheere S, Sanca S, Semo L, Van Damme P, Van Puyvelde L and De Kimpe N. (2004) Use of medicinal plants and pharmaceuticals by indigenous communities in the Bolivian Andes and Amazon. Bull World Health Organ. 82(4): 243-250.

Waldstein A and Adams C. (2006) The interface between medical anthropology and medical ethnobiology. J R Anthropol Inst. 12(s1):95-118.

White RE and McCarthy MB. (1986) Active site mechanics of liver microsomal cytochrome P-450. Arch Biochem Biophys. 246(1): 19-32.

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE and Fojo T. (2017) Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Lancet Oncol. 18(1): 143-154.

Zhang D, Luo D, Ding D and Lu C. (2012) Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharmacol Sin B. 2: 549-561.

Zhang Z, Sibbesen O, Johnson RA and Ortiz de Montellano PR. (1998) The substrate specificity of cytochrome $P45_{0cam}$. Bioorg Med Chem. 6(9): 1501-1508.

Zhang Z, Zhu M and Tang W. (2009) Metabolite identification and profiling in drug design: current practice and future directions. Curr Pharm Des. 15(19): 2220-2235.